TCRX Q3 2024 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-73.0% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$33M-3109.8% margin

Net Income

-$30M-2849.1% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+95.7%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$348M

Total Liabilities

$119M

Stockholders' Equity

$229M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$4M	-73.0%
Gross Profit	$1M	$4M	-73.0%
Operating Income	-$33M	-$25M	-31.8%
Net Income	-$30M	-$23M	-30.0%